Pulmonary Disease in Diabetes

Overview

Journal J Diabetes

Specialty Endocrinology

Date 2023 Dec 29

PMID 38156437

Authors

Zachary Bloomgarden

Affiliations

Soon will be listed here.

Citing Articles

Exploring Gender Differences in the Association Between TyG Index and COPD: A Cross-Sectional Study from NHANES 1999-2018.

Guo J, Yang J, Wang J, Liu W, Kang Y, Li Z Int J Chron Obstruct Pulmon Dis. 2024; 19:2001-2010.

PMID: 39253040 PMC: 11381934. DOI: 10.2147/COPD.S473089.

References

Almagro P, Boixeda R, Diez-Manglano J, Gomez-Antunez M, Lopez-Garcia F, Recio J . Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease. Int J Chron Obstruct Pulmon Dis. 2020; 15:755-764. PMC: 7166051. DOI: 10.2147/COPD.S238214. View

Diez-Manglano J, Asin Samper U . Type-1 diabetes and pulmonary function tests. A meta-analysis. Respir Med. 2022; 203:106991. DOI: 10.1016/j.rmed.2022.106991. View

Yu O, Suissa S . Metformin and Cancer: Solutions to a Real-World Evidence Failure. Diabetes Care. 2023; 46(5):904-912. DOI: 10.2337/dci22-0047. View

Chowdhury B, Luu A, Luu V, Kabir M, Pan Y, Teoh H . The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun. 2020; 524(1):50-56. DOI: 10.1016/j.bbrc.2020.01.015. View

Teague T, Payne S, Kelly B, Dempsey T, McCoy R, Sangaralingham L . Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Respir Res. 2022; 23(1):91. PMC: 9004115. DOI: 10.1186/s12931-022-02001-0. View

Nassif M, Qintar M, Windsor S, Jermyn R, Shavelle D, Tang F . Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021; 143(17):1673-1686. DOI: 10.1161/CIRCULATIONAHA.120.052503. View

Gojevic T, Van Ryckeghem L, Jogani S, Frederix I, Bakelants E, Petit T . Pulmonary hypertension during exercise underlies unexplained exertional dyspnoea in patients with Type 2 diabetes. Eur J Prev Cardiol. 2022; 30(1):37-45. DOI: 10.1093/eurjpc/zwac153. View

Albogami Y, Cusi K, Daniels M, Wei Y, Winterstein A . Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care. 2021; 44(6):1344-1352. PMC: 8247488. DOI: 10.2337/dc20-1794. View

Davis W, Knuiman M, Kendall P, Grange V, Davis T . Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004; 27(3):752-7. DOI: 10.2337/diacare.27.3.752. View

10.

Li C, Xiao Y, Hu J, Hu Z, Yan J, Zhou Z . Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People. J Clin Endocrinol Metab. 2021; 106(11):3367-3380. DOI: 10.1210/clinem/dgab553. View

11.

Pradhan R, Lu S, Yin H, Yu O, Ernst P, Suissa S . Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022; 379:e071380. PMC: 9623550. DOI: 10.1136/bmj-2022-071380. View

12.

Bagheri M, Agrawal V, Annis J, Shi M, Ferguson J, Freiberg M . Genetics of Pulmonary Pressure and Right Ventricle Stress Identify Diabetes as a Causal Risk Factor. J Am Heart Assoc. 2023; 12(15):e029190. PMC: 10492967. DOI: 10.1161/JAHA.122.029190. View

13.

Tseng C . Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis. 2022; 17:285-295. PMC: 8843794. DOI: 10.2147/COPD.S345796. View

14.

Kumar V, Nawroth P . Is the association between diabetes mellitus and pulmonary fibrosis real?. Nat Rev Endocrinol. 2021; 17(12):703-704. DOI: 10.1038/s41574-021-00577-z. View

15.

Jonas K, Kurzyna M, Mroczek E, Chrzanowski L, Mularek-Kubzdela T, Skoczylas I . Impact of diabetes mellitus on disease severity and patient survival in idiopathic pulmonary arterial hypertension: data from the Polish multicentre registry (BNP-PL). Cardiovasc Diabetol. 2023; 22(1):177. PMC: 10347845. DOI: 10.1186/s12933-023-01885-6. View

16.

Su J, Li M, Wan X, Yu H, Wan Y, Hang D . Associations of diabetes, prediabetes and diabetes duration with the risk of chronic obstructive pulmonary disease: A prospective UK Biobank study. Diabetes Obes Metab. 2023; 25(9):2575-2585. DOI: 10.1111/dom.15142. View

17.

Khateeb J, Fuchs E, Khamaisi M . Diabetes and Lung Disease: A Neglected Relationship. Rev Diabet Stud. 2018; 15:1-15. PMC: 6760893. DOI: 10.1900/RDS.2019.15.1. View

18.

Nundlall N, Playford D, Strange G, Davis T, Davis W . Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. J Clin Med. 2021; 10(19). PMC: 8509549. DOI: 10.3390/jcm10194503. View

19.

Kazmirczak F, Prins K . Diabetes Enters Stage Right: Genetic Association Studies Suggest Diabetes Promotes Pulmonary Hypertension and Right Ventricular Dysfunction. J Am Heart Assoc. 2023; 12(15):e030954. PMC: 10492981. DOI: 10.1161/JAHA.123.030954. View

20.

Kopf S, Groener J, Kender Z, Fleming T, Brune M, Riedinger C . Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes. Respiration. 2018; 96(1):29-40. DOI: 10.1159/000488909. View